Main menu
Edison Group
  • Home
  • Equities

    Equities

    View All Equities

    Equities by Sector

    Pharnext

    MCap

    1m

    Last close

    EUR0.10

    ▲ 0.03 (42.86%)

    MGI – Media and Games Invest

    MCap

    EUR235m

    Last close

    EUR1.50

    ▲ 0.35 (30.21%)

    AGBA

    MCap

    USD211m

    Last close

    USD2.83

    ▲ 0.48 (20.43%)

  • Sectors

    Sectors

  • Investment Strategy

    Investment Strategy

    View All

    Latest

  • Thematics

    Thematics

    View All Thematics

    Latest

  • Audiovisual

    Audiovisual

    View All Audiovisual

    Latest

Arovella Therapeutics – executive interview

Arovella Therapeutics – executive interview

Arovella Therapeutics — 1 video in collection

More on this equity

Arovella Therapeutics is an Australian biotechnology company specialised in immunoncology with a focus on the invariant natural killer T (iNKT) cell therapy platform, which was in-licensed from Imperial College London in July 2021. The platform can be combined with chimeric antigen receptors (CARs) to target blood cancers, with a potential of being an allogeneic ‘off-the-shelf’ therapy. This was followed by the in-licensing of a novel monoclonal antibody targeting a Dickkopf-1 (DKK1) peptide from MD Anderson Cancer Center in December 2021. Arovella plans to combine the DKK1-targeting technology with the iNKT cell therapy platform in the future. With recent fund-raising activity, we believe the company has sufficient funds for its development activities until CY23.

In this video, CEO Michael Baker provides an update on Arovella’s recent milestones and strategy.

< Previous
Next >

You may also be interested in these:

Healthcare

Interview with David Veitch, CEO of Basilea Pharmaceutica

Healthcare

Ultimovacs – executive interview

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free